These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2697597)

  • 61. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
    Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.
    Sucak GT; Aki SZ; Yüzbaşioğlu B; Akyürek N; Yağci M; Bağriaçik U; Haznedar R
    Leuk Lymphoma; 2011 Jul; 52(7):1281-9. PubMed ID: 21599578
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
    Jacobson JL; Hussein MA; Barlogie B; Durie BG; Crowley JJ;
    Br J Haematol; 2003 Aug; 122(3):441-50. PubMed ID: 12877671
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
    D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
    AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis.
    Penz MZ; Fiebiger WC; Valencak JB; Osterreicher C; Ba-Ssalamah A; Formanek M; Brodowic T; Chott A; Raderer M
    Anticancer Res; 2001; 21(4B):3049-52. PubMed ID: 11712809
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P; Collacciani A; Maccarone C; Casale R
    Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
    Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
    Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
    Mathiot C; Teillaud JL; Elmalek M; Mosseri V; Euller-Ziegler L; Daragon A; Grosbois B; Michaux JL; Facon T; Bernard JF
    J Clin Immunol; 1993 Jan; 13(1):41-8. PubMed ID: 8445043
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Histology and immunohistology of bone marrow biopsy in multiple myeloma.
    Pileri S; Poggi S; Baglioni P; Montanari M; Sabattini E; Galieni P; Tazzari PL; Gobbi M; Cavo M; Falini B
    Eur J Haematol Suppl; 1989; 51():52-9. PubMed ID: 2627992
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients.
    García-Sanz R; González-Fraile MI; Mateo G; Hernández JM; López-Berges MC; de las Heras N; Fernández-Calvo J; Ortega F; Portero JA; Bárez A; Galende J; Orfão A; San Miguel JF
    Int J Cancer; 2004 Dec; 112(5):884-9. PubMed ID: 15386370
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
    Pasqualetti P; Colantonio D; Casale R
    Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic variables and clinical staging in multiple myeloma.
    Cavo M; Galieni P; Zuffa E; Baccarani M; Gobbi M; Tura S
    Blood; 1989 Oct; 74(5):1774-80. PubMed ID: 2790201
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment.
    Carlson K; Aström G; Nyman R; Ahlström H; Simonsson B
    Acta Radiol; 1995 Jan; 36(1):9-14. PubMed ID: 7833177
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients.
    Bataille R; Grenier J; Sany J
    Blood; 1984 Feb; 63(2):468-76. PubMed ID: 6362753
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.
    Larsen JT; Chee CE; Lust JA; Greipp PR; Rajkumar SV
    Blood; 2011 Sep; 118(10):2702-7. PubMed ID: 21750316
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ki-67 Immunostaining and its Correlation with Microvessel Density in Patients with Mutiple Myeloma.
    Himani B; Meera S; Abhimanyu S; Usha R
    Asian Pac J Cancer Prev; 2016; 17(5):2559-64. PubMed ID: 27268630
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Prognostic factors in multiple myeloma].
    Boccadoro M; Bianchi A; Dianzani U; Frieri R; Gallone G; Massaia M; Omede P; Palumbo A; Pileri A
    Haematologica; 1989 Oct; 74(5 Suppl):347-57. PubMed ID: 2512219
    [No Abstract]   [Full Text] [Related]  

  • 80. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.
    Bakkus MH; Bouko Y; Samson D; Apperley JF; Thielemans K; Van Camp B; Benner A; Goldschmidt H; Moos M; Cremer FW
    Br J Haematol; 2004 Sep; 126(5):665-74. PubMed ID: 15327517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.